SYNCOMF19.23

Syncom Formulations (India) Limited

· Pharma & Health
₹ CrorePeersHESTERBIONGLFINEWINDLASJAGSNPHARMAMRUTANJANINDOCOSAIPARENTMcap ₹1,808 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)58.5054.26103.88103.88
Receivable Days (DSO)143.1584.4282.4582.45
Payable Days (DPO)67.0056.18122.90123.36
Cash Conversion Cycle (days)134.6582.5063.4362.97
Working Capital Turnover1.572.212.162.20
Asset Turnover0.651.130.920.92
Cash Conversion (CFO/Net Income)-0.240.470.760.76
CFO/EBITDA-0.200.430.750.75
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.